Effects of XXXX Level on Lower Urinary Tract Symptoms.

@entity1 @entity251 @entity263 @entity1067 @entity342 @entity6802 @entity1486
UNASSIGNED: @entity6802 ( @entity6802 ) are common in older @entity1 and are frequently associated with @entity1067 ( @entity1067 ). The relationship between @entity1067 and endogenous total @entity251 (TT) levels has been widely studied. The aim of this post hoc analysis was to determine the association between @entity6802 and endogenous TT levels in a subset of @entity1 participating in the 2013 @entity263 Awareness Week, a U.S. community-based @entity263 screening program. @entity1 completed the International Prostate Symptom Score (I-PSS) questionnaire, prostate size was estimated by a digital rectal examination, and serum TT and @entity1486 levels were measured. Mean TT levels (ng/dl) did not significantly correlate with prostate size category (r = +.03, p = .69): normal, 419.2 (n = 106); enlarged, 394.7 (n = 71); abnormal, 416.4 (n = 7); and abnormal/suspicious, 515.2 (n = 19). Mean TT levels (ng/dl) did not significantly correlate with I-PSS category (r = -.06, p = .40): none, 468.5 (n = 15); mild, 414.0 (n = 138); moderate, 397.4 (n = 66); and severe, 437.9 (n = 7). Mean TT levels (ng/dl) did not significantly correlate with I-PSS quality of life rating (r = -.13, p = .055): delighted, 474.5 (n = 43); pleased, 424.6 (n = 65); mostly satisfied, 361.2 (n = 63); mixed, 448.2 (n = 29); mostly dissatisfied, 337.2 (n = 17); and unhappy, 435.8 (n = 6). Adjustment for prostate size or @entity1486 levels yielded similar findings. In conclusion, endogenous TT levels did not correlate with @entity6802 or prostate size, and these findings support the saturation theory in which TT is not able to induce further @entity342 -stimulated prostate tissue growth due to receptor saturation. Any worsening of @entity6802 following @entity251 replacement therapy in hypogonadal @entity1 may be related to stimulation of prostatic cells previously deprived of @entity251 .
